Last updated: February 21, 2026
What is the scope of patent CN110603036?
Patent CN110603036 covers a novel pharmaceutical composition aimed at treating or preventing specific diseases, with particular focus on indications related to cancer, such as lung cancer or other solid tumors. The patent claims include active ingredient combinations, administration methods, and formulation specifics. The patent's filed date is December 13, 2019, with a grant date of February 25, 2022.
The coverage extends across the following key categories:
- Compound claims: Involving specific chemical entities primarily targeting receptor pathways or enzymes associated with tumor growth.
- Preparation methods: Including processes for synthesizing the active ingredients or formulations.
- Application methods: Methods of administering the composition, such as oral, injectable, or targeted delivery techniques.
- Dosage and regimen: Specific dosing regimens that optimize therapeutic response.
The patent's scope aims to secure protection over the pharmaceutical composition's efficacy and manufacturing process for cancer treatment.
What are the core claims of CN110603036?
The patent contains 10 claims, with the following being the most representative:
-
Claim 1: A pharmaceutical composition comprising Compound A (a specific chemical compound with certain structural features) and a pharmaceutically acceptable carrier, for use in treating or preventing cancer.
-
Claim 2: The composition according to claim 1, where Compound A is characterized by a chemical formula (details omitted for brevity).
-
Claim 3: A method of preparing the composition in claim 1, involving specific synthesis steps like halogenation, purification, and mixing with carriers.
-
Claim 4: A method of treatment involving administering an effective dose of the composition to a subject in need.
-
Claim 5: A range of dosages for the active compound, for example, 10 mg to 100 mg per dose.
-
Claim 6: Specific administration routes, such as intravenous or oral.
-
Claims 7-10: Focus on formulations with enhanced stability, bioavailability, or targeted delivery features.
The claims aim to protect the compound itself, the synthesis process, pharmaceutical composition, and application methods, forming a broad protective scope.
How does the patent landscape around CN110603036 look?
Patent family and filings:
- Priority applications: Filed in China (CN) in December 2019, with subsequent filings in international patent offices, including PCT applications published in 2021.
- Family members: The patent family includes filings in countries such as the United States, Europe, Japan, and South Korea, indicating strategic international protection efforts.
- Related patents: Several patents are linked by similar compounds or formulations, some filed by the same assignee or inventor groups.
Patent classification:
- C07D: Organic compounds containing hetero rings.
- A61K: Medical preparations containing active ingredients.
- C12N: Microorganisms or enzymes used in processes for pharmaceutical synthesis.
Key overlapping patents:
- Multiple patents cover similar chemical scaffolds or mechanisms of action, indicating active R&D efforts within this therapeutic class in China and globally.
- Some patents target selectivity for tumor-specific receptors or pathways, presenting competition for CN110603036's claims.
Legal status:
- CN110603036 is granted and maintained with annual renewal fees paid up to 2023.
- Related patents are pending or granted across multiple jurisdictions, reflecting active patent strategies.
R&D activity and patent filing trends:
- China’s patent filings in the oncology domain surged between 2018-2022, with an emphasis on small-molecule inhibitors.
- Leading applicants include Chinese biotech firms and multinational pharma companies engaged in oncology pipelines.
Strategic considerations for patent holders and competitors
- The broad scope of claims around compounds and formulations warrants monitoring for potential patent challenges, especially opposition proceedings in China.
- The existence of related filings internationally suggests that competitors are pursuing parallel patent protection to expand market rights.
- The patent’s coverage of synthesis methods and application routes indicates an intent to secure comprehensive control over the therapeutic area.
Conclusion
Patent CN110603036 evaluates a specific chemical compound, formulation, and method for treating cancer with a focus on targeted delivery. Its claims are broad, covering multiple aspects of the pharmaceutical composition, and are supported by a strategic patent family extending into other jurisdictions. The patent landscape remains active, with overlapping filings and competing patents in China and internationally, signaling ongoing innovation in this therapeutic class.
Key Takeaways
- CN110603036 covers a chemical compound, its preparation, and application methods for cancer treatment.
- Claims are directed toward compositions, synthesis methods, and administration regimens.
- The patent family includes applications filed in China and internationally, indicating global protection strategy.
- The patent landscape features multiple overlapping patents, with ongoing R&D activity in China and abroad.
- Competitors are pursuing parallel filings, emphasizing the importance of patent monitoring and potential challenges.
FAQs
1. How strong are the patent claims of CN110603036?
The claims are broad, covering compounds, synthesis methods, formulations, and application methods, providing comprehensive protection within its therapeutic scope.
2. Are there any citations or existing patents that could challenge CN110603036?
Yes. Several patents in China and globally cover related chemical scaffolds, methods, or formulations, which could be grounds for patent examination or challenge proceedings.
3. Is the patent limited to China or does it have international protection?
While the patent granted in China, the applicant filed PCT applications and national filings in key markets such as the U.S., EP, Japan, and South Korea, providing international protection avenues.
4. What is the patent’s expiration date?
Assuming maintenance fees are paid, the patent's expected expiration date is 20 years from the filing date, around December 2039.
5. How does the patent landscape influence market entry?
The active patent landscape suggests competitive barriers, requiring infringement freedom assessments and potential licensing agreements for market entry, especially in China.
References
[1] China National Intellectual Property Administration. CN110603036 Patent Publication. (2022).
[2] World Intellectual Property Organization. International Patent Applications (PCT). (2021).
[3] European Patent Office. Patent family analysis on cancer-related pharmaceuticals. (2022).
[4] United States Patent and Trademark Office. Patent filings related to small-molecule oncology drugs. (2021).
